Efcacy and safety of elagolix in moderate to severe endometriosis associated pain: a systematic review and meta analysis

eview question / Objective The aim of this study is to comprehensively analyze evidence of elagolix in the treatment of moderateto-severe endometriosis-associated pain.Condition being studied Endometriosis-related pain, such as dysmenorrhea, non-menstrual pelvic pain, and difficulties with sexual intercourse, severely impairs the physical and mental health of patients and imposes a heavy economic burden.Elagolix is an oral GnRH antagonist that has been approved by the FDA for the treatment of endometriosis.It inhibits the secretion of estrogen in a dose-dependent manner and allows for a rapid reversal of estrogen suppression shortly after discontinuation.Therefore, it can be conveniently dosed to balance effectiveness and safety. METHODSSearch strategy Search: (((((Elagolix[Title/ A b s t r a c t ] ) O R ( R -( + ) -4 -( 2 -( 5 -( 2 -fl u o ro -3m e t h o x y p h e n y l ) -3 -( 2 -fl u o r o -6 -(trifluoromethyl)benzyl)-4-methyl-2,6-dioxo-3,6d i h y d r o -2 H -p y r i m i d i n -1 -y l ) -1phenylethylamino)butyrate[Title/Abstract])) OR (elagolix sodium[